Publication | Closed Access

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

InflammationChronic Inflammatory DiseasesAnti-inflammatoryAutoimmune DiseaseImmunologyAutoimmunityRestores Clinical ResponseBiological TherapyImmune-mediated Inflammatory DiseasesUlcerative ColitisImmunotherapyMedicineRheumatoid Arthritis